Family of NLRP3 inhibitors is differentiated by novel structure, central nervous system penetration, and potential for improved safety and efficacyRICHMOND, Calif. (BUSINESS WIRE) #aging BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the mol.